AQST — Aquestive Therapeutics, Inc.
Is AQST overbought or oversold? Here is the current MarketMoodz read.
Aquestive Therapeutics, Inc. (AQST) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $4.55. The rating moved from Strong Oversold to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$4.55
- Last changeMoved from Strong Oversold to Oversold on October 1, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Aquestive Therapeutics, Inc. (AQST) is a small-cap specialty pharma company centered on an oral thin-film delivery platform with a handful of commercial products and a pipeline that offers upside via regulatory milestones or partnership deals. Revenue generation is currently modest and concentrated, so near-term performance hinges on commercial execution, payer access, and operational stability. The broader market’s recent risk-off tone and ongoing payer/pricing pressures increase sensitivity to disappointing news or the need for external financing. Positive data readouts, new approvals, or strategic collaborations would be clear catalysts; conversely, reimbursement setbacks, manufacturing issues, or funding constraints could materially weaken prospects.
Key factors
- Aquestive Therapeutics, Inc. (AQST) owns a proprietary drug delivery platform (oral thin-film technology) that differentiates certain products versus traditional dosage forms and supports niche commercialization and licensing opportunities.
- Existing commercial products provide recurring revenue but remain modest in scale and concentrated, so near-term cash flow is limited and growth depends on commercial execution and new product launches or partnerships.
- Pipeline and partnering optionality: clinical-stage assets and the potential for out-licensing or co-promotion deals create upside if regulatory milestones or commercial agreements are achieved.
- Payer and reimbursement dynamics are critical — coverage decisions and pricing pressure (including policy-driven negotiations) will materially affect revenue potential for specialty products.
- Macro and market sentiment: recent risk-off tone and light volumes reduce near-term likelihood of strong directional moves absent company-specific catalysts.
- Operational execution (manufacturing scale-up, supply chain resilience, and sales force effectiveness) will determine how efficiently incremental revenue translates to margins and cash runway.
Risks
- Reimbursement and pricing pressure from Medicare negotiation, PBMs, and payer scrutiny that can reduce realized prices or restrict access.
- High product and revenue concentration; underperformance of one or two products could materially reduce top-line and accelerate funding needs.
- Regulatory or clinical setbacks for pipeline assets that would delay or eliminate anticipated catalysts.
- Cash burn and financing risk: limited cash runway or the need to raise capital could lead to dilution or unfavorable partner deals.
- Manufacturing and supply chain disruptions that impair product availability or increase costs, especially for thin-film manufacturing.
- Competitive threats from larger pharma entrants, generics, or alternative delivery technologies that could capture market share.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AQST — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.